The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2021 | MRD for decision making in follicular lymphoma
Jessica Okosun, MA, MB BChir, MRCP, FRCPath, PhD, Barts Cancer Institute, London, UK, speaks on the role of measurable residual disease (MRD) in minimizing late toxicities and general decision making. Dr Okosun reports that there is a lack of sensitive tools to detect plasma circulating tumor DNA (ctDNA) to determine MRD levels in the field of follicular lymphoma. Dr Okosun also comments that although more work needs to be done before MRD can be implemented across all types of lymphoma, MRD may become a valuable tool in the monitoring of toxicities in the future. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
